Table 5 Sensitivity analysis of multiple logistic regression models for primary and secondary outcomes in recruitment years of 2015–2020, 2017–2020 and 2018–2020.

From: Comparative effectiveness of two intravenous immunoglobulin products in children with Kawasaki disease, a nationwide cohort study

Characteristic

Year

TBSF group

Privigen group

OR

95%CI

P value

n (%)

n (%)

Primary outcome

 IVIG resistance

2015–2020

280 (9.7)

45 (9.4)

0.72

0.52–0.99

0.041

2017–2020

164 (9.5)

45 (9.4)

0.73

0.52–1.02

0.062

2018–2020

114 (10.1)

40 (8.8)

0.58

0.40–0.84

0.004

Secondary outcome

 Coronary artery involvement

2015–2020

109 (3.8)

7 (1.5)

0.38

0.18–0.82

0.041

2017–2020

56 (3.2)

7 (1.5)

0.43

0.20–0.95

0.036

2018–2020

37 (3.3)

7 (1.5)

0.43

0.19–0.96

0.039

 Recurrence

2015–2020

43 (1.5)

4 (0.8)

0.60

0.22–1.68

0.332

2017–2020

16 (0.9)

4 (0.8)

0.95

0.32–2.83

0.920

2018–2020

7 (0.6)

4 (0.9)

1.47

0.43–5.02

0.541

  1. Expressed as n (%), OR, Odds ratio; CI, Confidence interval; IVIG, Intravenous immunoglobulin; TBSF, Taiwan Blood Services Foundation.